Meet Us At FlandersBio 2012

audioneditor — Wed, 16 May 2012 10:10:22 +0000

ModiQuest and ModiQuest Research will be participating in the 8th annual FlandersBio Knowledge For Growth Conference on the 24 May.

For companies involved in developing antibody-based therapeutics or diagnostics, we will be on hand to discuss how ModiQuest Research can develop products up to preclinical candidate stages, through our antibody services and expertise.

Raymond Egging, ModiQuest Research VP Business Development and Jos Raats, CEO will be there. Please stop by our booth for a chat.

Can’t make the conference? Just call us on +31 412 846 000 for an informal discussion and let’s see how we can help your antibody project.

ModiQuest is Moving!

audioneditor — Fri, 30 Mar 2012 13:59:55 +0000

Company Relocating To New Commercial Life Sciences Park

As of May 1, 2012, ModiQuest will be moving to new commercial facilities at the Life Sciences Park (LSP) in Oss.

The new facilities offer a dynamic commercial environment, housing biotechnology companies with significant synergies, fostering the potential for commercial partnerships, collaborations and networking, in the grounds of one of the biggest pharma companies in the world; MSD.

ModiQuest’s new 400-500 square metre premises will house all of ModiQuest’s activities, including antibody discovery, development, antibody reformatting, phage display, high throughput mouse hybridoma generation and antibody production services, plus ModiQuest’s own research activities into antibody-based rheumatoid arthritis therapies and diagnostics.

From May 1, ModiQuest’s contact details will be:

Postal address:
ModiQuest
LSP Oss
Molenweg 79
5349 AC Oss

Visiting address:
ModiQuest
LSP Oss
Molenweg 50
5349 AC Oss

Meet Us At Bio-Europe

audioneditor — Sun, 18 Mar 2012 14:08:35 +0000

ModiQuest and ModiQuest Research will be participating in the Spring 2012 BioEurope conference in Amsterdam, The Netherlands from 19-21 March.

If you are attending, please met up with us.

Jos Raats, ModiQuest CEO, will also be discussing ModiQuest’s rheumatoid arthritis preclinical candidates which are available for licensing or as a co-development partnering programme.

Can’t make the conference? Just call us on +31 (0)24 361 42 53 and let’s see how we can work together.

ModiQuest Invited To Speak At UCB

audioneditor — Wed, 22 Feb 2012 09:40:24 +0000

Effective Rheumatoid Arthritis Antibody Treatment Identified From Company’s Antibody Generation Technologies and Mouse Modelling, Showcasing At UCB

08 March 2012: ModiQuest, Nijmegen, The Netherlands: Jos Raats, CEO of ModiQuest has been invited to UCB, England on March 8th to give a seminar on their novel, effective antibody-based treatments for Rheumatoid Arthritis.

BioPharmaceuticals – What Next In 2012?

Kapler — Wed, 21 Dec 2011 15:32:43 +0000

I’m often asked about developments in this market, but this year, 2011, has seen one real trend – outsourcing. Big pharma and biotech are always looking to develop their pipelines, but what has struck me is that some pharmaceutical companies in the UK are going about it in a whole different way.

Pharma-Biotech Collaboration

Attracting smaller companies to collaborate is one way of identifying novel, high-value platforms and targets to fill the pipeline. Big companies such as Glaxo SmithKline (UK) are creating a large complex around their facilities in Stevenage (Stevenage Biosciences Catalyst) to foster this type of relationship. There doesn’t seem to be shortage of innovative biotech companies with late-stage drugs that are looking for a sales and marketing partner. This is where the expertise of the established pharmaceuticals comes into play, their established network means that these new drugs are easy to get onto the market.

Big Pharma Turning to Bio-generics: the next big thing in 2012

Looking ahead, I’m predicting that the production of bio-generics will take a big leap. In this market the big players will also be the companies that currently produce their proprietary biologicals. One way of protecting their interest will be the production and sales of their off-patent compounds as generics. That is, when the patent runs out on a licensed drug, the same pharmaceutical company will produce the generic. This ensures these companies a considerable market share, since their branded products are known and proven on the market, as are their production processes and marketing channels.

By Jos Raats, CEO ModiQuest Research

Three top tips for antibody generation

Kapler — Wed, 21 Dec 2011 09:37:30 +0000

Nowadays there are multiple methods to generate monoclonal antibodies (i.e. hybridoma, B-cell selection and cloning, phage display, transgenic animals etc). The main issue is to define the antibody product profile before you embark on an antibody generation process.

1. Think about what the antibody has to do

Firstly you need to think about the profile of the antibody, consider what it is that you really need it for. What characteristics does the antibody have to have in regard to affinity, isotype, effector functions, cross reactivity, biological efficacy, size, and stability for example?

Monoclonal antibodies are useful tools for both medical treatment, diagnostics as well as research. Taking this into account, the application will define the specification and critical parameters. These issues can be dealt with during the process of antibody generation, optimisation and production in a QBD (Quality By Design) approach using a combination of currently available (recombinant) antibody technologies.

2. Determine the limiting factor for your specific approach

Is it time, money or something else? Only when you understand this can you determine the best approach for your budget and purpose.

3. Finally, find the right service provider that can integrate and coordinate all your requirements to generate the required antibody molecule

Ensure that the antibody service provider has an integrated platform of various technologies and methods that are required to generate and deliver the antibody you require.

By Jos Raats, CEO ModiQuest Research

Mercator Award Winner 2011

audioneditor — Thu, 01 Dec 2011 10:58:25 +0000

A total of sixteen companies entered into the annual competition, which provides 5000 Euro and a work of art as the prize.

CEO, Jos Raats commented “We’re proud to be the Mercator award winner this year, which is a testament to the hard work of the superb team we have here, and the fact that we’re delivering a great antibody service that’s meeting the needs of our world-wide pharmaceutical and biotechnology clients. ”

For more information, contact Jos Raats at info@modiquestresearch.com.

Rheumatoid Arthritis Therapeutic Antibodies

audioneditor — Wed, 30 Nov 2011 21:00:06 +0000

ModiQuest Research Delivers Novel Rheumatoid Arthritis Therapeutic Antibodies

30 November 2011: ModiQuest Research, Nijmegen, The Netherlands: ModiQuest Research, the full service provider for antibody generation, engineering and optimization, has successfully generated novel antibody therapeutic leads and diagnostics for rheumatoid arthritis (RA). Using its extensive antibody generation technology platform, which includes phage display and high throughput mouse hybridoma generation, the company identified specific anti-citrulline antibodies that demonstrate high efficacy levels in preclinical RA models.

The company has been especially successful in supporting a variety of autoimmune disease projects in addition to rheumatoid arthritis, including multiple sclerosis, and lupus erythematosus. By using a combination of a unique technology service platform and a growing collection of immunological reagents for autoimmune disease research, ModiQuest provides the antibody expertise, as well as customised antigens, monoclonal antibodies and enzymes specifically designed for early diagnosis as well as therapeutic research. View our range of auto-immune bioreagents on our website.

Research scientists at ModiQuest Research have definitive expertise in autoimmune disease allowing them to provide deep insights drawn from their own extensive experience in the field, and an unrivalled suite of products and services specifically aimed at supporting autoimmune disease research. Examples of autoimmune products and services that ModiQuest Research provides include: an effective mix of anti-collagen monoclonal antibodies for generating collagen antibody-induced arthritis (CAIA) in mice; readily available ELISA assay kits for evaluating autoimmune-associated peptide de-imination; custom development of diagnostic assays for other autoimmune disease pathways, and bespoke arthritis preclinical mouse efficacy studies for analyzing the therapeutic effects of client compounds in rheumatoid arthritis mouse models.

“We have demonstrable success in generating anti-collagen antibody products for rheumatoid arthritis research and we have huge experience in the area of auto-immune and inflammatory disease” said Dr Jos Raats CEO of ModiQuest Research. “We are currently helping a number of companies potentiate autoimmune therapies and diagnostic kits by the application of our antibody products and expertise.”

ModiQuest Research, which was established in 2005, has extensive knowledge and experience of antibody technologies. With its state-of-the-art facilities, proprietary technology and end-to-end support services, ModiQuest Research is superbly placed to support the development and production of antibody-based therapies and diagnostics in the most efficient and cost effective way possible. If you are active in autoimmune research then Modiquest Research can help you maximize the potential of your project.

End

High resolution image attached or available from Claire England,
Kapler Communications claire@kapleronline.com Ref: MQR/JOB/006

About ModiQuest Research

ModiQuest Research has extensive knowledge and experience of antibody technologies. With state-of-the-art facilities and proprietary tools, ModiQuest Research supports the development and production of antibody-based therapies and diagnostics in the most efficient and cost effective way possible.

Established since 2005, ModiQuest Research is based in Nijmegen, The Netherlands, with a global customer base that includes small and large leading pharmaceutical and diagnostic companies as well as academic research teams.

ModiQuest B.V is a sister company that develops new antibody therapies and diagnostics for rheumatoid arthritis and inflammatory disorders.

For more information:

For press information, please contact:
Alexandra Jones, Kapler Communications
Knowledge Centre, Wyboston Lakes, Great North Road,
Wyboston, Bedfordshire, MK44 3BY, UK
Tel: +44 (0)1480 479280; Fax: +44 (0)1480 470343 alexandra@kapleronline.com

ModiQuest Research contact:
Dr. Jos Raats, ModiQuest Research B.V. Heyendaalseweg 135, Nijmegen, 6525 AJ, The Netherlands
email: jraats@modiquestresearch.com

ModiQuest Invited To Present At Bayer

audioneditor — Tue, 22 Nov 2011 10:15:58 +0000

Effective Rheumatoid Arthritis Antibody Treatment Identified From Company’s Antibody Generation Technologies and Mouse Modelling, Showcasing At Bayer

22 November 2011: ModiQuest Research, Nijmegen, The Netherlands: Jos Raats, CEO of ModiQuest has been invited to Bayer, Germany on 22 November to give a seminar on their novel, effective antibody-based treatments for Rheumatoid Arthritis.

The discoveries were made as a result of ModiQuest Research’s state-of-art proprietary technology platforms for efficient antibody generation, antibody cloning and reformatting, stable cell line development and antibody production facilities. These were used in combination with the company’s own highly effective rheumatoid arthritis mouse model, to identify and characterise promising antibody preclinical candidates. First and second generation mouse and human monoclonal antibodies have been identified and characterised as being able to slow or halt the onset and progression of arthritis in preclinical studies.

Together with early diagnostic testing which is already on the market, the discoveries by ModiQuest herald new possibilities for rheumatoid arthritis treatment that can be applied before the onset of clinical symptoms and irreversible joint damage. For established rheumatoid arthritis, the group demonstrated that these new antibodies have the potential to significantly decrease arthritis symptoms, in combination with current anti-inflammatory treatments.

For further information, contact Jos Raats, CEO ModiQuest, at jraats@modiquestresearch.com.

ModiQuest At Human Antibodies and Hybridomas (HAH) 2011

audioneditor — Wed, 26 Oct 2011 10:16:03 +0000

Technologies For Developing New Antibody Treatments Showcasing At Human Antibodies and Hybridomas (HAH) 2011

25 October 2011: ModiQuest Research, Nijmegen, The Netherlands: Combining accurate, early diagnostic tests for autoimmune disease, and new antibody treatment options are two themes being presented by antibody technology experts, ModiQuest Research at HAH 2011 (7-9 November 2011, Cannes, France). ModiQuest Research’s technology includes monoclonal antibody generation and specialist immunological reagents to support the research and development of new antibody therapies and diagnostics. President and CEO, Dr Jos Raats will present latest data on new antibodies and early diagnostics for rheumatoid arthritis, using their hybridoma and phage display platforms.

Dr Raats said, “The Human Antibodies and Hybridomas event will be a great opportunity to share knowledge with others in the field of antibody development. I am honoured to be delivering a paper entitled ‘Anti-Citrulline Antibody as Novel Therapeutic Drug in early Rheumatoid Arthritis,’ detailing ModiQuest Research’s development of a novel therapy for Rheumatoid Arthritis (RA). Using our antibody generation technologies, this new drug candidate was developed by focussing on targets like Deiminated Peptide-Epitopes (DPE), since a number of studies indicated that these deimination modifications could be responsible for the initial triggering of autoimmunity and the breaking of tolerance. We use the same technologies to support our clients in the development of new antibody therapies and diagnostics. ”

Modiquest Research are proud to be sponsors of Human Antibodies & Hybridomas 2011. This year the scientific programme will include keynote lectures, contributed papers and poster presentations emphasising all key aspects of human antibody and hybridoma technology, applications and engineering. The scope of the conference falls broadly into eight main session categories; infectious diseases, autoimmunity, molecular biology, emerging technologies, clinical applications, therapeutic antibodies, cancer and anti-infective antibodies.

ModiQuest Research offers an intelligent approach to antibody generation, cloning and cell line production. Its offering includes monoclonal antibody generation, cell line services, plus antibody cloning and sequencing. Products available in the range include immunological reagents to enable early research into new antibody therapeutics and diagnostics. These products contain unique and highly specialised reagents to enable research in autoimmune disease, infectious diseases including fungal and parasitic diseases and oncology and are available to purchase online via ModiQuest’s website.

For more information about ModiQuest and to see Dr Raats in action, please click on http://bit.ly/MQR003video or visit www.modiquestresearch.com

End

High resolution image attached or available from Claire England,
Kapler Communications claire@kapleronline.com Ref: MQR/JOB/005a

About ModiQuest Research

Established since 2004, ModiQuest Research is based in Nijmegen, The Netherlands, with a global customer base that includes small and large leading pharmaceutical and diagnostic companies as well as academic research teams.

ModiQuest B.V is a sister company that develops new antibody therapies and diagnostics for rheumatoid arthritis and inflammatory disorders.

For more information:

ModiQuest Research contact:
Dr. Jos Raats, ModiQuest Research B.V. Heyendaalseweg 135, Nijmegen, 6525 AJ, The Netherlands
email: jraats@modiquestresearch.com